Medpace (NASDAQ:MEDP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Medpace (NASDAQ:MEDP) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

Other equities research analysts also recently issued reports about the stock. Mizuho set a $660.00 price target on shares of Medpace in a research note on Friday, January 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. TD Cowen upped their price target on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a report on Friday, October 24th. Truist Financial set a $555.00 price objective on Medpace in a report on Monday, October 27th. Finally, Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $491.27.

Medpace Trading Down 1.2%

NASDAQ MEDP opened at $610.90 on Friday. The firm’s 50 day simple moving average is $582.94 and its 200 day simple moving average is $514.69. The firm has a market capitalization of $17.21 billion, a price-to-earnings ratio of 42.72, a P/E/G ratio of 2.05 and a beta of 1.43. Medpace has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the business earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities research analysts forecast that Medpace will post 12.29 earnings per share for the current year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 21,503 shares of the company’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the sale, the president owned 15,000 shares in the company, valued at approximately $8,934,900. The trade was a 58.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO August J. Troendle sold 59,025 shares of the stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 387,925 shares of company stock valued at $233,386,647 in the last three months. Insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Wasatch Advisors LP lifted its holdings in Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after buying an additional 116,354 shares during the period. Mawer Investment Management Ltd. boosted its position in Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares during the last quarter. Baillie Gifford & Co. grew its holdings in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after acquiring an additional 62,503 shares during the period. Finally, Invesco Ltd. grew its holdings in Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares during the period. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.